The WHO Classification of Tumors of the Breast, 4th edition, is an update to the 3rd edition that was published in 2003, and covers all neoplastic and preneoplastic lesions of the breast. Changes to the 4th edition include new aspects and changes to the terminology that reflect our present-day knowledge of these lesions. Definitions for histopathological diagnosis are complemented by a description of clinical features, epidemiology, macroscopy, genetics, and prognostic and predictive features. In this review of the WHO classification, we have focused on invasive carcinomas, precursor lesions, and some benign epithelial proliferations.

Keywords:
Diagnostic criteria, Pathology, WHO classification, Breast Cancer
1.
Lakhani S, Ellis I, Schnitt S, et al.: WHO Classification of Tumours of the Breast, 4th ed. Lyon, IARC Press, 2012.
2.
Tavassoli FA, Devilee P (eds): Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon, IARC Press, 2003.
3.
Orvieto E, Maiorano E, Bottiglieri L, et al.: Clinico-pathologic characteristics of invasive lobular carcinoma of the breast: results of an analysis of 530 cases from a single institution. Cancer 2008;113:1511-1520.
4.
Talman ML, Jensen MB, Rank F: Invasive lobular breast cancer. Prognostic significance of histological malignancy grading. Acta Oncol 2007;46:803-809.
5.
Rakha EA, Aleskandarany M, El-Sayed ME, et al.: The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast. Eur J Cancer 2009;45:1780-1787.
6.
Rody A, Karn T, Liedtke C, et al.: A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res 2011;13:R97.
7.
Lee H, Jung SY, Ro JY, et al.: Metaplastic breast cancer: Clinicopathological features and its prognosis. J Clin Pathol 2012;65:441-446.
8.
Abati AD, Kimmel M, Rosen PP: Apocrine mammary carcinoma. A clinicopathologic study of 72 cases. Am J Clin Pathol 1990;94:371-377.
9.
Niemeier LA, Dabbs DJ, Beriwal S, et al.: Androgen receptor in breast cancer: Expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol 2010;23:205-212.
10.
Weigelt B, Horlings HM, Kreike B, et al.: Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 2008;216:141-150.
11.
Foschini MP, Krausz T: Salivary gland-type tumors of the breast: A spectrum of benign and malignant tumors including ‘triple negative carcinomas' of low malignant potential. Semin Diagn Pathol 2010;27:77-90.
12.
Wetterskog D, Lopez-Garcia MA, Lambros MB, et al.: Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers. J Pathol 2012;226:84-96.
13.
Capella C, Eusebi V, Mann B, et al.: Endocrine differentiation in mucoid carcinoma of the breast. Histopathology 1980;4:613-630.
14.
Lacroix-Triki M, Suarez PH, MacKay A, et al.: Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type. J Pathol 2010;222:282-298.
15.
Toikkanen S, Kujari H: Pure and mixed mucinous carcinomas of the breast: A clinicopathologic analysis of 61 cases with long-term follow-up. Hum Pathol 1989;20:758-764.
16.
Miremadi A, Pinder S, Lee A, et al.: Neuroendocrine differentiation and prognosis in breast adenocarcinoma. Histopathology 2002;40:215-222.
17.
Lopez-Bonet E, Alonso-Ruano M, Barraza G, et al.: Solid neuroendocrine breast carcinomas: Incidence, clinico-pathological features and immunohistochemical profiling. Oncol Rep 2008;20:1369-1374.
18.
Wei B, Ding T, Xing Y, et al.: Invasive neuro endocrine carcinoma of the breast: A distinctive subtype of aggressive mammary carcinoma. Cancer 2010;116:4463-4473.
19.
Chen L, Fan Y, Lang RG, et al.: Breast carcinoma with micropapillary features: Clinicopathologic study and long-term follow-up of 100 cases. Int J Surg Pathol 2008;16:155-163.
20.
American Joint Committee on Cancer: AJCC cancer staging manual, 7th ed. New York, Springer, 2010.
21.
Prasad ML, Osborne MP, Giri DD, et al.: Microinvasive carcinoma (T1mic) of the breast: clinicopathologic profile of 21 cases. Am J Surg Pathol 2000;24:422-428.
22.
Lucas FV, Perez-Mesa C: Inflammatory carcinoma of the breast. Cancer 1978;41:1595-1605.
23.
Hartman M, Czene K, Reilly M, et al.: Incidence and prognosis of synchronous and metachronous bilateral breast cancer. J Clin Oncol 2007;25:4210-4216.
24.
Huo D, Melkonian S, Rathouz PJ, et al.: Concordance in histological and biological parameters between first and second primary breast cancers. Cancer 2011;117:907-915.
25.
Fritz AG (ed): International Classification of Diseases for Oncology: ICD-O, 3rd ed. Geneva, World Health Organization, 2000.
26.
Page DL, Dupont WD, Rogers LW, et al.: Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer 1985;55:2698-2708.
27.
The Consensus Committee: Consensus conference on the classification of ductal carcinoma in situ. Hum Pathol 1997;28:1221-1225.
28.
Fitzgibbons PL, Henson DE, Hutter RVP: Benign breast changes and the risk for subsequent breast cancer - An update of the 1985 consensus statement. Arch Pathol Lab Med 1998;122:1053-1055.
29.
Bilous M: Breast core needle biopsy: Issues and controversies. Mod Pathol 2010;23 Suppl 2:S36-45.
30.
Page DL, Salhany KE, Jensen RA, et al.: Subsequent breast carcinoma risk after biopsy with atypia in a breast papilloma. Cancer 1996;78:258-266.
31.
Collins LC, Carlo VP, Hwang H, et al.: Intracystic papillary carcinomas of the breast: A reevaluation using a panel of myoepithelial cell markers. Am J Surg Pathol 2006;30:1002-1007.
32.
Hill CB, Yeh IT: Myoepithelial cell staining patterns of papillary breast lesions: From intraductal papillomas to invasive papillary carcinomas. Am J Clin Pathol 2005;123:36-44.
33.
Nassar H, Qureshi H, Volkanadsay N, et al.: Clinicopathologic analysis of solid papillary carcinoma of the breast and associated invasive carcinomas. Am J Surg Pathol 2006;30:501-507.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.